Used in cancer immunotherapy to stimulate the immune system by activating antigen-presenting cells through CD40 receptor engagement. Enhances tumor antigen presentation and promotes T-cell activation, supporting anti-tumor responses. Investigated in clinical trials for solid tumors and hematologic malignancies, often in combination with checkpoint inhibitors or chemotherapy. Also explored for use in vaccine adjuvancy to boost immune response.